Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc.

Published: Friday, April 26, 2013
Last Updated: Friday, April 26, 2013
Bookmark and Share
The acquisition will diversify and expand Emergent’s biodefense franchise.

Acquisition will add product sales from HPPD’s marketed chemical countermeasure, RSDL (Reactive Skin Decontamination Lotion). The acquisition offers Emergent an opportunity to leverage its core capabilities in manufacturing, government contracting, government sales, and product distribution as it looks to substantially expand sales of RSDL in the attractive and growing chemical countermeasure market.

“This acquisition directly supports our ongoing growth plan, which includes acquiring revenue generating, profitable products and businesses that address the needs of U.S. and allied foreign governments across the CBRN spectrum,” stated Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions. “Our relationships, combined with those of HPPD, with the U.S. Government and foreign ministries of defense, as well as worldwide distributor relationships addressing first responder markets, should enable us to grow revenues from RSDL and to expand and enhance Emergent’s leadership position as a premier supplier of CBRN countermeasures.”

The Canadian Department of National Defence and the U.S. Department of the Army have both played a central role in the development and licensing of RSDL, which has been cleared by the U.S. Food and Drug Administration (FDA), Health Canada, the European Union’s Medicines and Healthcare products Regulatory Agency and Australia’s Therapeutics Goods Administration for the removal or neutralization of chemical warfare agents from the skin, including nerve agents, mustard gas, and toxins.

After closing of the transaction, Emergent will assume responsibility for an existing 5-year (2012-2017) procurement contract with the U.S. Department of Defense (DoD) to provide RSDL to active military personnel, as well as a supply agreement with NATO that allows NATO countries to purchase RSDL through the NATO Support Agency through 2015, with up to two additional option years. Emergent intends to pursue various potential growth opportunities for RSDL, including expanding sales to additional U.S. government agencies and domestic and foreign first responders, as well as new foreign ministries of defense.

Emergent plans to retain HPPD’s current staff of 16 employees who will be integrated into Emergent’s Biodefense Division. HPPD’s operations will continue to be located in Princeton, New Jersey and Hattiesburg, Mississippi.

The acquisition of HPPD, which is subject to customary closing conditions including the receipt of certain third party consents and regulatory approvals, is expected to close in the third quarter of 2013.

Emergent expects the acquisition to contribute to revenue and net income, exclusive of transaction costs, beginning in 2013. After giving effect to this acquisition, Emergent is reaffirming its annual 2013 guidance of $290 to $310 million in total revenues and $20 to $30 million in net income. The company also reaffirms its first quarter revenue guidance of $40 to $50 million. Actual first quarter 2013 financial results will be announced on May 2, 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves Expanded Use of Emergent BioSolutions' BioThrax
Emergent BioSolutions has announced that the FDA has approved its supplemental Biologics License Application to expand the label of BioThrax®(Anthrax Vaccine Adsorbed) to include post-exposure prophylaxis (PEP) of disease following suspected or confirmed Bacillus anthracis exposure.
Wednesday, November 25, 2015
Emergent BioSolutions Awarded $19.7 Million BARDA Contract
Company receives its first Ebola-related BARDA task order for its HHS-designated center for innovation in advanced development and manufacturing.
Friday, July 24, 2015
Oxford University, GSK, and Emergent BioSolutions Fight Ebola
Company announces initiation of a prime boost study of Ebola vaccine candidates.
Thursday, May 14, 2015
Emergent BioSolutions Receives FDA Approval of Anthrasil
Company’s Anthrax Immune Globulin, for use in the treatment of inhalational anthrax.
Friday, March 27, 2015
Emergent Signs Agreements with Oxford University, GSK, and NIAID
200L scale production leverages Emergent's unique expertise and capabilities in MVA-based vaccine product development and manufacturing.
Friday, March 20, 2015
Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax
Large scale manufacturing of BioThrax in Building 55 will increase annual production capacity from 7-9 million doses to a target of 20-25 million doses.
Friday, September 26, 2014
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate.
Tuesday, May 06, 2008
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!